Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, ...

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

Alto Neuroscience, Inc. (NYSE: ANRO) shares fell first thing Tuesday. The company, a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today ...

A new study reveals how chronic pain triggers depression through structural changes in the brain's hippocampus.

A large twin study found that adverse childhood experiences increase the risk of developing treatment-resistant depression.

Scientists have identified two specific types of brain cells that behave differently in people with depression, offering a ...

An AI-based machine learning tool identified depression in 71% of people with the condition from under a minute of free speech. The findings may enable more widespread screening for the condition. The ...

A new study found that depression may increase the risk of menstrual pain through factors like sleep disturbances. The findings suggest that treating sleep and mental health issues may help relieve ...

Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory ...

AbbVie ABBV is set to report first-quarter 2026 results on April 29. While the company’s immunology portfolio will remain the ...

ADHD traits are 2.4x more common in chronic pain patients, suggesting neurodevelopmental factors amplify pain through anxiety ...